Vink MA - Search Results

1

Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice.

van der Velden YU, Villaudy J, Siteur-van Rijnstra E, van der Linden CA, Frankin E, Weijer K, Schermer E, Vink MA, Berkhout B, Sanders RW, van Gils MJ. van der Velden YU, et al. Among authors: vink ma. AIDS Res Hum Retroviruses. 2018 Sep;34(9):790-793. doi: 10.1089/AID.2018.0114. Epub 2018 Aug 22. AIDS Res Hum Retroviruses. 2018. PMID: 30003812

2

In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Marzio G, Verhoef K, Vink M, Berkhout B. Marzio G, et al. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6342-7. doi: 10.1073/pnas.111031498. Epub 2001 May 15. Proc Natl Acad Sci U S A. 2001. PMID: 11353837 Free PMC article.

3

Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription.

Marzio G, Vink M, Verhoef K, de Ronde A, Berkhout B. Marzio G, et al. J Virol. 2002 Mar;76(6):3084-8. doi: 10.1128/jvi.76.6.3084-3088.2002. J Virol. 2002. PMID: 11861878 Free PMC article.

4

Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.

Berkhout B, Verhoef K, Marzio G, Klaver B, Vink M, Zhou X, Das AT. Berkhout B, et al. J Neurovirol. 2002 Dec;8 Suppl 2:134-7. doi: 10.1080/13550280290101102. J Neurovirol. 2002. PMID: 12491165 Review.

5

Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.

Das AT, Zhou X, Vink M, Klaver B, Berkhout B. Das AT, et al. Expert Rev Vaccines. 2002 Oct;1(3):293-301. doi: 10.1586/14760584.1.3.293. Expert Rev Vaccines. 2002. PMID: 12901570 Free article. Review.

6

Viral evolution as a tool to improve the tetracycline-regulated gene expression system.

Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Marzio G, Berkhout B. Das AT, et al. J Biol Chem. 2004 Apr 30;279(18):18776-82. doi: 10.1074/jbc.M313895200. Epub 2004 Feb 2. J Biol Chem. 2004. PMID: 14761948 Free article.

7

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition.

Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. Das AT, et al. J Virol. 2004 Mar;78(5):2601-5. doi: 10.1128/jvi.78.5.2601-2605.2004. J Virol. 2004. PMID: 14963165 Free PMC article.

8

A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Huthoff H, Das AT, Vink M, Klaver B, Zorgdrager F, Cornelissen M, Berkhout B. Huthoff H, et al. J Virol. 2004 May;78(9):4907-13. doi: 10.1128/jvi.78.9.4907-4913.2004. J Virol. 2004. PMID: 15078972 Free PMC article.

9

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. Westerhout EM, et al. Nucleic Acids Res. 2005 Feb 1;33(2):796-804. doi: 10.1093/nar/gki220. Print 2005. Nucleic Acids Res. 2005. PMID: 15687388 Free PMC article.

10

Alternative tRNA priming of human immunodeficiency virus type 1 reverse transcription explains sequence variation in the primer-binding site that has been attributed to APOBEC3G activity.

Das AT, Vink M, Berkhout B. Das AT, et al. J Virol. 2005 Mar;79(5):3179-81. doi: 10.1128/JVI.79.5.3179-3181.2005. J Virol. 2005. PMID: 15709038 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters